Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Inv. presentation
Outlook Therapeutics, Inc. (ONS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones · Prescription Drug User Fee Act goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration ISELIN, N.J., August 14, 2023 — Outlook Therapeutics, Inc. , a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of wet AMD, today announced recent corporate highlights and financial results for its fiscal third quarter ended June 30, 2023. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, commented, “We continue to be focused on our pre-launch activi..."
05/15/2023 8-K Quarterly results
Docs: "Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update ● Upcoming Prescription Drug User Fee Act goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration ● Pre-launch commercial activities continue in preparation for potential approval and launch of ONS-5010 ISELIN, N.J., May 15, 2023 – Outlook Therapeutics, Inc. , a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal second quarter ended March 31, 2023. “We continue to make sig..."
12/29/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
02/14/2022 8-K Quarterly results
Docs: "Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update · Outlook Therapeutics remains on track to submit new U.S. FDA Biologics License Application for first ophthalmic formulation of bevacizumab · Commercial launch planning underway · Financed through the anticipated approval of the ONS-5010 BLA ISELIN, N.J., February 14, 2022 — Outlook Therapeutics, Inc. , a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal first quarter ended December 31, 2021. Recent Corporate Highlights · Expanded commercial team with appoi..."
12/22/2021 8-K Quarterly results
Docs: "Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update · Positive clinical data reported for ONS-5010 / LYTENAVA™ in 2021 from multiple clinical trials, including statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial for wet age-related macular degeneration · Recent financing activities expected to provide funding through the anticipated approval of the ONS-5010 biologics license application expected in the first calendar quarter of 2023 · Pre-launch commercial planning underway in anticipation of ONS-5010 approval ISELIN, N.J., December 22, 2021 — Outlook Therapeutics, Inc. , a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formu..."
08/13/2021 8-K Quarterly results
Docs: "Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update · Reported positive, statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial of ONS-5010 / LYTENAVA™ for the treatment of wet age-related macular degeneration · On track to submit new U.S. BLA for ONS-5010 in the first quarter of calendar 2022 and pre-commercial launch planning underway ISELIN, N.J., August 13, 2021 — Outlook Therapeutics, Inc. , a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal third quarter ended June ..."
05/14/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
12/28/2020 8-K Quarterly results
Docs: "Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update · All planned clinical trials for ONS-5010 / LYTENAVA™ wet AMD BLA now fully enrolled or completed · Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 with new BLA filing expected in second half of 2021 MONMOUTH JUNCTION, N.J., December 23, 2020 — Outlook Therapeutics, Inc. , a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced its corporate highlights and financial results for its fiscal year ended September 30, 2020. Outlook Therapeutics also provided a clinical de..."
08/14/2020 8-K Quarterly results
05/15/2020 8-K Quarterly results
02/14/2020 8-K Quarterly results
12/19/2019 8-K Quarterly results
05/15/2019 8-K Quarterly results
Docs: "Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019"
02/14/2019 8-K Quarterly results
12/18/2018 8-K Asset disposition, Quarterly results
Docs: "Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018"
05/15/2018 8-K Quarterly results
Docs: "Form of Warrant to Purchase Common Stock of Oncobiologics, Inc",
"Purchase Agreement by and between Oncobiologics, Inc. and GMS Tenshi Holdings Pte. Limited",
"Amendment to Investor Rights Agreement",
"Oncobiologics Reports Second Quarter Financial Results for Fiscal 2018",
"Oncobiologics Announces $15 Million Private Placement Offering"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy